MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen

Leukemia. 2001 Feb;15(2):283-5. doi: 10.1038/sj.leu.2402019.

Authors

U zur Stadt¹, D O Harms, S Schlüter, M Schrappe, U Goebel, H Spaar, G Janka, H Kabisch

Affiliation

¹ Department of Pediatric Hematology and Oncology, University of Hamburg, Germany.

PMID: 11236947
DOI: 10.1038/sj.leu.2402019

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Child
Humans
Immunophenotyping
Neoplasm, Residual*
Polymerase Chain Reaction
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology*
Prognosis
Treatment Outcome*